This message was sent to ##Email##
|
|
|
|
|
| |
SCAI
 Founder's Lecture: Ongoing Scrutiny: Evidence-Based Science in Interventional Cardiology
Roxanna Mehran, MD, MSCAI
Interventional cardiology, as a medical specialty, has faced intense scrutiny from its origin that continues through present day. From early studies in angioplasty and balloons to more recent trials involving 20,000 patients at a time, practitioners face extensive professional and public scrutiny and a demand for ever-increasing precision in how they treat their patients. Approval processes for devices and medications follow clinical trials, but it is the practitioners' post-market surveillance that defines their clinical practices and treatment strategies. Dr. Roxanna Mehran will take us on a 40-year journey of medical scrutiny with a unique presentation that promises a few twists and turns — and even some surprises.
 Hildner Lecture: A Pivotal Time for Interventional Cardiology
Anthony N. DeMaria, MD
Since its inception by Andreas Gruentzig, interventional cardiology has been a wonder of innovation, and conveyed enormous benefits to patients with coronary and structural heart disease. However, several recent trials have raised questions regarding the prognostic and even symptomatic benefit of coronary interventions in patients with stable angina. As technological advances continue to be pursued, it will be essential to take stock of pathophysiology, and to conduct rigorous studies to define those individuals with stable angina most likely to benefit from an intervention. Simultaneously, therapies for structural lesions are expanding dramatically, including approaches to address mitral and tricuspid valve disorders. Interventional approaches to structural heart disorders will grow exponentially in the future. Dr. Anthony DeMaria will discuss how new research developments and structural innovations will change the face of interventional cardiology forever more.
 Mullins Lecture: Celebrating Women Who Paved the Way to Pediatric Cardiology Today
Jacqueline Kreutzer, MD, FSCAI
The field of pediatric cardiology has evolved with tremendous contributions by female physicians who played an integral role in the evolution of the specialty. Dr. Jacqueline Kreutzer will review and highlight the pivotal roles played by female physicians and the innovations and contributions they have made to the field of pediatric cardiology — enriching patient care, saving countless lives, and impacting the way we practice medicine today.
SCAI
Pulsara
In the cohort of patients, the utilization of the Pulsara platform decreased the average door-to-balloon times by 22% in patients with acute STEMI arriving at the emergency department. This effect was maintained when looking at the subset of all STEMI cases reportable to CMS. Researchers also observed modest improvements in meeting the less than 60-minute, less than 90-minute benchmarks, and improvements in the resource utilization. Read the full Critical Pathways in Cardiology publication here.
READ MORE
|
|
|
|
|
| |
Cardiovascular Business
Medtronic PLC announced one-year results from the CRYO4PERSISTENT atrial fibrillation (AF) study of ablation with the Arctic Front Advance(TM) Cryoballoon to isolate the pulmonary veins in patients with symptomatic persistent AF. The Arctic Front Advance Cyroablation System is not approved for treating persistent AF in the United States.
READ MORE
 |
|
Society guidelines state the need to reduce dye in high risk patients as part of a strategy to reduce risk of AKI in the cath lab. Osprey Medical’s DyeVert™ Plus System is the only technology proven to consistently monitor and reduce dye dosage delivered to patients undergoing coronary angiography procedures.
|
|
HealthDay News via The Cardiology Advisor
A magnetically levitated centrifugal continuous-flow circulatory pump was superior to a mechanical-bearing axial continuous-flow pump at two years for patients with advanced heart failure, according to a study published online in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American College of Cardiology, held from March 10 to 12 in Orlando, Florida.
READ MORE
Healio
Six months of dual antiplatelet therapy (DAPT) was noninferior to 12 months' duration, but shorter therapy was associated with a significantly increased risk for myocardial infarction (MI) in patients with acute coronary syndrome who underwent percutaneous coronary intervention with a drug-eluting stent, according to new data from the SMART-DATE trial.
In the intention-to-treat analysis, the cumulative rate of the primary endpoint of MACCE — a composite of all-cause death, MI or stroke at 18 months — did not differ significantly in patients assigned to six months of DAPT compared with those assigned to at least 12 months of DAPT.
READ MORE
 |
|
After implementing process changes including the use of Pulsara to coordinate care, St. Elizabeth Healthcare reduced their door-to-balloon time by 30%. Read the case study!
|
|
TCTMD
Patients with atherosclerotic cardiovascular disease treated with the PCSK9 inhibitor evolocumab (Repatha; Amgen) have a consistent reduction in the risk of cardiovascular events regardless of baseline high-sensitivity C-reactive protein (hsCRP) levels, according to a new analysis of the FOURIER trial.
"We found that the relative benefit of evolocumab was consistent across the range of hsCRP, with an approximate 20 percent reduction in major adverse CV events compared to placebo," lead investigator Erin Bohula, MD, told TCTMD.
READ MORE
For a complete list of job postings, click here.
To post your resume, click here.
| Date |
Event |
Location |
| March 21-24, 2018 |
Scottsdale Interventional Forum (SIF) |
Scottsdale, AZ
|
| April 7-8, 2018 |
Houston Shock Symposium |
Houston, TX
|
| April 12-14, 2018 |
2018 ARCH: Advanced Revascularization – Chapter XI
|
St. Louis, MO
|
| April 25-28, 2018 |
SCAI 2018 Scientific Sessions |
San Diego, CA
|
| April 27-28, 2018 |
Women in Innovations Physician Leadership Summit |
San Diego, CA
|
| April 27-28, 2018 |
Fellows Summit for Complex Cases |
San Diego, CA
|
| Oct. 12-13,
2018 |
SCAI Shock 2018 |
Boston, MA
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
